Bifidobacterium animalis subsp. lactis BB-12 attenuates diabetic retinopathy through gut microbiota modulation: evidence for the gut–retinal axis
Frontiers in Cellular and Infection Microbiology · 06.11.2025 · 15
DOI: 10.3389/fcimb.2025.1681943 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 06.11.2025. Verfasst von Jiayi Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Gastrointestinal Microbiome, Probiotics, Bifidobacterium animalis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Previous studies have shown that Bifidobacterium animalis subsp. lactis BB-12 plays a role in maintaining the intestinal barrier and regulating inflammation; however, its potential connection to ocular diseases has not been thoroughly explored. Diabetic retinopathy (DR) is a common ocular complication of diabetes and is closely associated with metabolic dysregulation. This study investigated whether BB-12 supplementation could affect systemic diabetic symptoms, the progression of DR, and the stability of gut microbiota. Materials and methods Diabetic db/db mice were utilized to monitor metabolic parameters, assess hepatic and lipid profiles, evaluate retinal function via ERG, and examine retinal morphology through OCT and HE staining. Treg/Th17 balance was analyzed by flow cytometry, and gut microbiota composition was profiled using 16S rRNA sequencing.
Results
The results showed that BB-12 reduced obesity, decreased hepatic steatosis, improved retinal blood vessel health and vision, and influenced both the Treg/Th17 balance and gut dysbiosis in diabetic mice.
Conclusions
These findings lay the groundwork for regulatory role of intestinal microbiota on systemic and ocular complications of diabetes, and further examination of the gut-retina axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, China.
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-sen University, Guangzhou, China.
Zitieren
APA
Lin, J., Cheng, Y., Ling, Y., Gu, S., Zhu, H., Li, M., Yu, H., Li, J., Luo, Q., Li, W., & Ling, S. (2025). Bifidobacterium animalis subsp. lactis BB-12 attenuates diabetic retinopathy through gut microbiota modulation: evidence for the gut–retinal axis. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1681943
Vancouver
Lin J, Cheng Y, Ling Y, Gu S, Zhu H, Li M, et al. Bifidobacterium animalis subsp. lactis BB-12 attenuates diabetic retinopathy through gut microbiota modulation: evidence for the gut–retinal axis. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1681943
BibTeX
@article{Lin2025,
author = {Lin, Jiayi and Cheng, Yaqi and Ling, Yumin and Gu, Simin and Zhu, Haocheng and Li, Meng and Yu, Huan and Li, Jianbing and Luo, Qian and Li, Weihua and Ling, Shiqi},
title = {Bifidobacterium animalis subsp. lactis BB-12 attenuates diabetic retinopathy through gut microbiota modulation: evidence for the gut–retinal axis},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
volume = {15},
doi = {10.3389/fcimb.2025.1681943}
}
EUVIMED